153 related articles for article (PubMed ID: 7703567)
1. [Amplification of c-myc and c-erbbeta-2(HER-2/neu) in breast cancer without axillary lymph node metastasis: correlation with other prognostic parameters].
Lizard-Nacol S; Arnould L; Riedinger JM; Arnal M; Collin F; Guerrin J
Bull Cancer; 1994 Sep; 81(9):780-4. PubMed ID: 7703567
[TBL] [Abstract][Full Text] [Related]
2. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer.
Berns EM; Klijn JG; van Putten WL; van Staveren IL; Portengen H; Foekens JA
Cancer Res; 1992 Mar; 52(5):1107-13. PubMed ID: 1737370
[TBL] [Abstract][Full Text] [Related]
3. Cathepsin-D and c-erb-B 2 have an additive prognostic value for breast cancer patients.
Scorilas A; Yotis J; Gouriotis D; Keramopoulos A; Ampela K; Trangas T; Talieri M
Anticancer Res; 1993; 13(5C):1895-900. PubMed ID: 7903524
[TBL] [Abstract][Full Text] [Related]
4. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
Champème MH; Bièche I; Hacène K; Lidereau R
Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157
[TBL] [Abstract][Full Text] [Related]
5. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization.
Persons DL; Borelli KA; Hsu PH
Mod Pathol; 1997 Jul; 10(7):720-7. PubMed ID: 9237184
[TBL] [Abstract][Full Text] [Related]
6. c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients.
Scorilas A; Yotis J; Stravolemos K; Gouriotis D; Keramopoulos A; Ampela K; Talieri M; Trangas T
Anticancer Res; 1995; 15(4):1543-7. PubMed ID: 7654043
[TBL] [Abstract][Full Text] [Related]
7. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis.
Tiwari RK; Borgen PI; Wong GY; Cordon-Cardo C; Osborne MP
Anticancer Res; 1992; 12(2):419-25. PubMed ID: 1349794
[TBL] [Abstract][Full Text] [Related]
8. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations.
Gaffey MJ; Frierson HF; Williams ME
Mod Pathol; 1993 Nov; 6(6):654-9. PubMed ID: 7905628
[TBL] [Abstract][Full Text] [Related]
9. Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis.
Varley JM; Swallow JE; Brammar WJ; Whittaker JL; Walker RA
Oncogene; 1987; 1(4):423-30. PubMed ID: 3330785
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis.
Guérin M; Barrois M; Terrier MJ; Spielmann M; Riou G
Oncogene Res; 1988; 3(1):21-31. PubMed ID: 2905033
[TBL] [Abstract][Full Text] [Related]
11. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P
Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
[TBL] [Abstract][Full Text] [Related]
12. HER-2/neu amplification predicts poor survival in node-positive breast cancer.
Borg A; Tandon AK; Sigurdsson H; Clark GM; Fernö M; Fuqua SA; Killander D; McGuire WL
Cancer Res; 1990 Jul; 50(14):4332-7. PubMed ID: 1973070
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for recurrent breast cancer: univariate and multivariate analyses including histologic grade and amplification of the c-erbB-2 proto-oncogene.
Tsuda H; Tsugane S; Fukutomi T; Nanasawa T; Yamamoto H; Hirohashi S
Jpn J Clin Oncol; 1992 Aug; 22(4):244-9. PubMed ID: 1359174
[TBL] [Abstract][Full Text] [Related]
14. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
[TBL] [Abstract][Full Text] [Related]
15. c-erbB-2 amplification in node-negative human breast cancer.
Ro JS; el-Naggar A; Ro JY; Blick M; Frye D; Fraschini G; Fritsche H; Hortobagyi G
Cancer Res; 1989 Dec; 49(24 Pt 1):6941-4. PubMed ID: 2573424
[TBL] [Abstract][Full Text] [Related]
16. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
Prati R; Apple SK; He J; Gornbein JA; Chang HR
Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
[TBL] [Abstract][Full Text] [Related]
17. Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis.
Scorilas A; Trangas T; Yotis J; Pateras C; Talieri M
Br J Cancer; 1999 Dec; 81(8):1385-91. PubMed ID: 10604737
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
19. Follow-up study of HER-2/neu amplification in primary breast cancer.
Clark GM; McGuire WL
Cancer Res; 1991 Feb; 51(3):944-8. PubMed ID: 1988136
[TBL] [Abstract][Full Text] [Related]
20. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1.
Tsuda H; Hirohashi S; Shimosato Y; Hirota T; Tsugane S; Yamamoto H; Miyajima N; Toyoshima K; Yamamoto T; Yokota J
Cancer Res; 1989 Jun; 49(11):3104-8. PubMed ID: 2566377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
